


RESEARCH ARTICLE

Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France

Laure-Amélie de Monteynard¹, Sophie Matheron^{2,3}, Sophie Grabar^{1,4,5}, Pierre de Truchis⁶, Jacques Gilquin⁷, Juliette Pavie⁸, Odile Launay^{9,10}, Jean-Luc Meynard¹¹, Marie-Aude Khuong-Josses¹², David Rey¹³, Aba Mahamat¹⁴, Rosemarie Dray-Spira¹, Anne Simon¹⁵, Dominique Costagliola¹, Sophie Abgrall^{1,16}*, on behalf of the FHDH-ANRS CO4[†]



OPEN ACCESS

Citation: de Monteynard L-A, Matheron S, Grabar S, de Truchis P, Gilquin J, Pavie J, et al. (2018) Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. *PLoS ONE* 13(10): e0205385. <https://doi.org/10.1371/journal.pone.0205385>

Editor: Graciela Andrei, Katholieke Universiteit Leuven Rega Institute for Medical Research, BELGIUM

Received: September 11, 2017

Accepted: September 25, 2018

Published: October 31, 2018

Copyright: © 2018 de Monteynard et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are not owned by the authors. SAS dataset "migrants1" is owned by the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Ministère de la Santé. French law requires that everyone who wants to share cohort data or clinical study data on humans must ask permission from the French data protection authority, la Commission Nationale de l'Informatique et des Libertés (CNIL), by filling a form which can be provided by Sophie Grabar at

1 Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRs 1136), Paris, France, **2** Sorbonne Paris cité, Université Paris Diderot, UMR 1137, Paris, France, **3** AP-HP, Hôpital Bichat-Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France, **4** Université Paris Descartes, Sorbonne Paris cité, Paris, France, **5** APHP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Unité de Biostatistique et Epidémiologie, Paris, France, **6** AP-HP, Hôpitaux Universitaires Paris-Ile de France-Ouest, Hôpital Raymond-Poincaré, Département de Médecine Aigüe Spécialisée, Garches, France, **7** AP-HP, Hôpital Hôtel-Dieu, Unité d'immunoinfectiologie, Paris, France, **8** AP-HP, Hôpital Européen Georges Pompidou, Service d'immunologie clinique, Paris, France, **9** Université Paris Descartes, Sorbonne Paris cité, Paris, France, **10** AP-HP, Hôpital Cochin, Paris, France, **11** AP-HP, Hôpital Saint Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France, **12** Centre Hospitalier Saint-Denis, Hôpital Delafontaine, Service des Maladies Infectieuses et Tropicales, Saint-Denis, France, **13** Hôpitaux Universitaire Strasbourg, Centre de Soins de l'Infection par le VIH, Strasbourg, France, **14** Centre Hospitalier Andrée Rosemon, Service des Maladies Infectieuses et Tropicales, Cayenne, France, **15** AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine interne, Paris, France, **16** AP-HP, Hôpital Antoine Béclère, Service de Médecine interne/Immunologie clinique, Clamart, France

* Current address: Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP INSERM U1018, Le Kremlin-Bicêtre, France.

† The full list of FHDH-ANRS-CO4 can be found in the Acknowledgments section.

* sophie.abgrall@aphp.fr

Abstract

Background

The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries.

Method

We studied antiretroviral-naïve heterosexual HIV-1-infected individuals enrolled in the FHDH-ANRS CO4 cohort in France who started cART between 2006 and 2011. Individuals originating from France (French natives), sub-Saharan Africa (SSA) and non-French West-Indies (NFW) were studied until 2012. Crude and adjusted rate ratios (aRR) of severe morbid events/deaths (AIDS-related and non-AIDS-related) were calculated using Poisson regression models stratified by sex, comparing each group of migrants to French natives.

the FHDH (sophie.grabar@iplesp.upmc.fr). For further information, please see: <https://www.cnil.fr/>. The authors did not have any special access to the data that others would not have.

Funding: The FHDH is supported by the ANRS ("France REcherche Nord&Sud Sida-hiv Hépatites"), INSERM, and the French Ministry of Health. Laure-Amélie de Monteynard was supported by a doctoral contract from Sorbonne Universités UPMC Paris Univ 06.

Competing interests: The authors have declared that no competing interests exist.

Results

Among 2334 eligible men, 1379 (59.1%) originated from France, 838 (35.9%) from SSA and 117 (5.0%) from NFW. SSA male migrants had a higher aRR for non-AIDS infections, particularly bacterial infections (aRR 1.56 (95% CI 1.07–2.29), $p = 0.0477$), than French natives. Among 2596 eligible women, 1347 (51.9%) originated from France, 1131 (43.6%) from SSA, and 118 (4.5%) from NFW. SSA and NFW female migrants had a higher aRR for non-AIDS infections, particularly non-bacterial infections (respectively, 2.04 (1.18–3.53) and 7.87 (2.54–24.4), $p = 0.0010$), than French natives. We observed no other significant differences related to geographic origin as concerns the aRRs for AIDS-related infections or malignancies, or for other non-AIDS events/deaths such as cardiovascular disease, neurological/psychiatric disorders, non-AIDS malignancies and iatrogenic disorders, in either gender.

Conclusion

Heterosexual migrants from SSA or NFW living in France have a higher risk of non-AIDS-defining infections than their French native counterparts. Special efforts are needed to prevent infectious diseases among HIV-infected migrants.

Introduction

In high-income countries, HIV-infected adults with controlled infection and high CD4 cell counts currently live longer than ever before [1], and the main causes of morbidity and mortality have switched from AIDS-defining to non-AIDS-defining disorders [2,3,4,5,6,7,8,9]. In western European countries, despite experiencing more AIDS-defining events [10,11], migrants from sub-Saharan Africa (SSA) have lower mortality than non-migrants, mainly owing to lower non-AIDS mortality [12]. In France, heterosexual migrant men originating from SSA and non-French West Indies (NFW), and non-migrant men, have a higher risk of new AIDS-defining events, serious non-AIDS events or death after cART initiation than non-migrant men who have sex with men (MSM), while this is not the case of women [9]. This latter study compared heterosexual individuals to MSM, two groups with different socioeconomic and lifestyle factors, and specific causes of morbidity were not assessed. In addition, no previous study has examined the specific morbidity of migrants compared to non-migrants. We therefore described and compared causes of severe morbidity and mortality between SSA or NFW migrant and non-migrant heterosexual HIV-infected men and women between 2006 and 2012.

Methods

Individuals

Created in 1989, the French Hospital Database on HIV (FHDH, ANRS CO4) is a large prospective cohort of HIV-infected individuals receiving care in one of 70 French participating hospitals, collecting standardized clinical, therapeutic and biological variables at each outpatient visit or hospital admission and/or at least every 6 months [13]. The only enrolment criteria are documented HIV-1 or HIV-2 infection, follow-up in a FHDH participating centre, and written informed consent. Data submitted by the participating centres to the data coordinating and analysis centre are anonymized, then encrypted. The FHDH was approved by the French data

protection agency (Commission Nationale de l'Informatique et des Libertés) on 27 November 1991 (Journal Officiel, 17 January 1992). For the present study, we selected antiretroviral-naive heterosexual HIV-1-infected individuals from the FHDH, aged at least 16 years, who started a first combined antiretroviral therapy (cART) between 1 January 2006 and 31 December 2011, at least one year prior to the database update (31 December 2012). Individuals were excluded if their first cART regimen was prescribed for pregnancy. Patients had to have at least one CD4 cell count and one plasma viral load (pVL) measurements within 6 months prior to treatment initiation and one CD4 cell count and one pVL measurements following cART initiation. Migrant status was based on the United Nations definition, as follows: "anyone born and having lived outside France and now residing in France, whatever their nationality and the duration of stay in France" [14]. All individuals originating from France, including the French West Indies (Martinique, Guadeloupe, French Guyana), SSA or NFW, were considered.

Coding causes of severe events

Severe events included any AIDS-defining event or death from AIDS [15] and any serious non-AIDS event or death from causes other than AIDS occurring between cART initiation and 31 December 2012. A serious non-AIDS event was defined as the primary underlying cause of any unscheduled hospitalization for more than 24 hours when an AIDS event was not the reason for hospitalization. If more than one non-AIDS event was notified for one hospitalization with no main reason notified in the discharge file, the most severe event was chosen as the cause for hospitalization in a hierarchical way: non-AIDS cancer, cardiovascular event, end-stage renal failure, acute liver failure, suicide attempt, infection, iatrogenic systemic event, then other systemic event. Hospitalization for a non-morbid cause (routine check-up, chemotherapy, blood transfusion, etc.) was not considered. If any of the following severe morbid events for which hospitalization is essential was reported outside the context of an hospitalization, ie non-AIDS-defining cancer, cardiovascular event (stroke, myocardial infarction or coronary revascularization), deep-vein thrombosis or pulmonary embolism, end-stage renal disease (dialysis or renal transplantation), decompensated liver disease, complicated diabetes mellitus, severe bacterial, fungal, viral or parasitic infection, acute neuropsychiatric diseases (e.g. suicide attempt), acute surgical conditions (e.g. gastrointestinal bleeding), it also counted as a serious non-AIDS event as proposed elsewhere [8,16]. All successive events were considered for each patient.

Severe events were categorized according to the Coding of Death in HIV (CoDe) (available at: <http://www.cphiv.dk/Portals/0/files/Code%20Protocol%202.3.pdf>), adapted to take AIDS and severe non-AIDS events into account, in addition to death. We grouped causes as follows: AIDS-defining infection (CoDe 01.1), AIDS-defining malignancy (CoDe 01.2), non-AIDS bacterial infection (CoDe 02.1), other non-AIDS infection (CoDe 02.2), liver-related disorder (CoDe 03 and 14), non-AIDS malignancy (CoDe 04), cardiovascular disease (CoDe 08, 09 and 24), respiratory disease (CoDe 13 and 25), renal failure and urogenital disease (CoDe 15 and 28), central neurological and psychiatric disorders (CoDe 19, 22 and 23), gastrointestinal disorders (CoDe 10 and 26), skin, rheumatic and peripheral neurological disorders (CoDe 27), haematological disease (CoDe 20), accidental/violent events (CoDe 16 and 17) and endocrine and metabolic disease (CoDe 05, 06 and 21), as proposed elsewhere [2]. In addition, owing to the large number of events, a category of "iatrogenic disorders" was created including any reported event, mainly cutaneous, hematological, hepatic or intestinal, associated with drug toxicity. Other causes not mentioned in this classification, and unknown causes, were classified as "other". Only categories with more than 20 events/deaths are presented here.

Statistical analysis

The Chi² and Kruskal-Wallis tests were used to compare the demographic, immunovirological and clinical characteristics of the individuals at cART initiation, across the three regions of origin, in men and in women. The number of severe events, person-years at risk, and incidence rates (IRs) of severe events (per 1000 person-years of follow-up) were calculated. Person-years of follow-up were calculated from the date of cART initiation to the date of death for known deceased individuals, last follow-up visit for individuals with no follow-up visit during the 6-month period before 31 December 2012 (last database update) or 31 December 2012 for the remainder of the cohort. Crude and adjusted IRs were estimated according to geographic origin, in men and in women. Poisson regression models were used to identify differences in morbidity/mortality according to geographic origin, in men and in women. Incidence rates (IRs) and rate ratios (RRs) were adjusted for the following characteristics at cART initiation: age, region of care (Paris area, other regions of metropolitan France plus the Reunion Island and French West Indies), CD4 cell count, pVL, AIDS status, hepatitis B and/or C infection and smoking status for each category of events/deaths, plus the body mass index for cardiovascular diseases. All analyses were done with SAS v9.4 software (SAS Institute, Inc, Cary, NC). A *p* value <0.05 was considered to denote statistical significance.

Results

Population

A total of 2334 men and 2596 women fulfilled the inclusion criteria for this study. The men's geographic origin was France in 1379 cases (59.1%), SSA in 838 (35.9%) and NFW in 117 (5.0%). The women's geographic origin was France in 1347 cases (51.9%), SSA in 1131 (43.6%) and NFW in 118 (4.5%) (Table 1). In each sex, SSA migrants were the youngest individuals and NFW migrants were the oldest. At cART initiation, in men and in women, NFW migrants had the lowest CD4 cell counts and the highest rate of AIDS, while individuals originating from France had the highest CD4 cell counts and the lowest rate of AIDS. Smoking was less prevalent among migrants than among French natives, in both genders.

Incidences and risks of severe events in men

During 6524 person-years of follow-up, a total of 771 severe events, including 27 deaths, were recorded in 495 men, of whom 299 were French natives, 167 SSA migrants and 29 NFW migrants. Overall, crude IRs of severe events were 118.7 per 1000 person-years for French natives, 116.4 for SSA migrants and 125.8 for NFW migrants. Adjusted IR of severe events was highest among SSA migrants (183.6 in French natives, 226.4 in SSA migrants and 163.1 in NFW migrants), with an adjusted rate ratio (aRR) of severe events among SSA migrants estimated as 1.23 (95% confidence interval (CI): 1.04–1.47) compared to French natives. When AIDS events and severe non-AIDS events were considered separately, SSA migrants had a higher aRR of both AIDS events (1.38 (95%CI: 0.96–1.99)) and non-AIDS events (1.19 (95% CI: 0.98–1.44)) than French natives. Within the different non-AIDS events categories, there was a higher aRR of non-AIDS infections among SSA migrants (1.58 (95%CI: 1.15–2.15)) than among French natives, due to a higher aRR of non-AIDS bacterial infections in SSA migrants than in French natives (Table 2). The main non-AIDS bacterial infection was acute pneumonia, with 61 cases (40.9%). No other significant differences were observed in the aRRs of cardiovascular diseases, neurological/psychiatric disorders, non-AIDS malignancies or iatrogenic effects according to geographic origin.

Table 1. Characteristics of the population at cART initiation according to geographic origin in heterosexual men and women (France, 2006–2011, n = 4930).

	Heterosexual men (n = 2334)				Heterosexual women (n = 2596)			
	France ^a N = 1379	SSA N = 838	NFW N = 117	P ^b	France ^a N = 1347	SSA N = 1131	NFW N = 118	P ^b
Age [years, median (IQR)]	43.7 (36.2–51.6)	40.3 (34.5–47.1)	45.4 (37.9–52.0)	<0.0001	38.6 (31.1–47.7)	34.3 (29.4–40.3)	42.1 (34.4–49.1)	<0.0001
Period of cART initiation [n (%)]								
2006–2007	553 (40.1)	338 (40.3)	77 (65.8)		511 (37.9)	465 (41.1)	73 (61.9)	
2008–2011	826 (59.9)	500 (59.7)	40 (34.2)	<0.0001	836 (62.1)	666 (58.9)	45 (38.1)	<0.0001
Region of care [n (%)]								
Paris area	584 (42.4)	650 (77.6)	45 (38.4)		660 (49.0)	826 (73.0)	45 (38.1)	
Southeast France	162 (11.7)	27 (3.2)	0 (0)		166 (12.3)	32 (2.8)	0 (0)	
Other/Reunion island	509 (36.9)	161 (19.2)	3 (2.6)		448 (33.3)	269 (23.8)	1 (0.9)	
French West Indies	124 (9.0)	0 (0)	69 (59.0)	<0.0001	73 (5.4)	4 (0.4)	72 (61.0)	<0.0001
CD4 cell count [n (%)]								
<200	523 (37.9)	348 (41.5)	55 (47.0)		412 (30.6)	399 (35.3)	47 (39.8)	
≥200–349	527 (38.2)	331 (39.5)	43 (36.7)		578 (42.9)	488 (43.2)	53 (44.9)	
≥350–499	222 (16.1)	121 (14.4)	11 (9.4)		251 (18.6)	178 (15.7)	12 (10.2)	
≥500	107 (7.8)	38 (4.5)	8 (6.8)	0.0159	106 (7.9)	66 (5.8)	6 (5.1)	0.0108
CD4 cell count [median (IQR)]	250 (122–342)	231 (120–321)	214 (56–299)	0.0008	270 (171–357)	251 (154–333)	235 (148–313)	0.0004
pVL [log10 copies/mL, median (IQR)]	4.88 (4.30–5.35)	4.84 (4.26–5.34)	4.92 (4.30–5.39)	0.7363	4.57 (3.88–5.10)	4.58 (3.91–5.11)	4.64 (3.99–5.10)	0.8677
AIDS status [n (%)]	230 (16.7)	164 (19.6)	34 (33.3)	<0.0001	166 (12.3)	171 (15.1)	22 (18.6)	0.0400
Hepatitis B antigen [n (%)]	53 (3.8)	89 (10.6)	4 (3.4)	<0.0001	34 (2.5)	75 (6.6)	4 (3.4)	<0.0001
Hepatitis C antibodies [n (%)]	36 (2.6)	20 (2.4)	3 (2.6)	0.9480	48 (3.6)	38 (3.4)	0 (0)	0.1156
Smoking status [n (%)]								
Never	281 (20.4)	375 (44.7)	63 (53.8)		337 (25.0)	701 (62.0)	61 (51.7)	
Previous	151 (10.9)	75 (9.0)	7 (6.0)		56 (4.2)	27 (2.4)	3 (2.5)	
Current	411 (29.8)	175 (20.9)	14 (12.0)		221 (16.4)	69 (6.1)	8 (6.8)	
Unknown	536 (38.9)	213 (25.4)	33 (28.2)	<0.0001	733 (54.4)	334 (29.5)	46 (39.0)	<0.0001
Body mass index [n (%)]								
<18	11 (0.8)	15 (1.8)	0 (0)		49 (6.6)	19 (1.7)	3 (2.5)	
≥18–30	1024 (74.3)	653 (77.9)	59 (50.4)		911 (67.6)	835 (73.8)	51 (43.2)	
>30	69 (5.0)	70 (8.4)	4 (3.4)		140 (10.4)	120 (10.6)	4 (3.4)	
Unknown	275 (19.9)	100 (11.9)	54 (46.2)	<0.0001	247 (18.3)	157 (13.9)	60 (50.9)	<0.0001
Follow-up time after cART initiation [years, median (IQR)]	2.6 (1.4–4.0)	2.6 (1.4–4.1)	2.3 (1.9–3.6)	0.1636	2.6 (1.5–4.0)	2.7 (1.6–4.1)	1.8 (1.0–3.5)	<0.0001

Data are counts (proportions) and median (interquartile range)

^aIncluding French West Indies (Martinique, Guadeloupe, French Guyana)

^bThe Chi2 and Kruskal-Wallis tests were used to compare the demographic, immunovirological and clinical characteristics of the individuals

Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral

<https://doi.org/10.1371/journal.pone.0205385.t001>

Incidences and risks of severe events in women

During a follow-up of 7324 person-years, a total of 624 severe events, including 48 deaths, were recorded in 413 women, of whom 213 were French natives, 181 SSA migrants and 18 NFW migrants. Overall, crude IRs of severe events were 87.0 per 1000 person-years among French natives, 82.2 among SSA migrants and 96.3 among NFW migrants. Within the different non-AIDS events categories, there was a higher aRR of non-AIDS infections among SSA

Table 2. Crude and adjusted incidence rates (IRs) per 1000 person-years (PY) and 95% confidence intervals (95% CI), and crude and adjusted rate ratios (RRs) and 95% CI of clinical events/deaths by geographic origin, in heterosexual men and women (Poisson regression, n = 4930, France, 2006–2012).

Clinical events	Geographic origin	Heterosexual men (n = 2334)						Heterosexual women (n = 2596)					
		People with event(s)	Events	Crude IRs per 1000 PY	Adjusted ^a IRs per 1000 PY	Crude RRs (95%CI)	Adjusted ^a RRs (95%CI)	People with event(s)	Events	Crude IRs per 1000 PY	Adjusted ^a IRs per 1000 PY	Crude RRs (95%CI)	Adjusted ^a RRs (95%CI)
						p-value	p-value					p-value	p-value
AIDS infections	France	71	87	22.4	26.3	1	1	43	51	13.6	10.3	1	1
	SSA	49	54	22.9	34.0	1.02 (0.73–1.43)	1.29 (0.86–1.94)	47	55	16.7	11.8	1.23 (0.84–1.80)	1.15 (0.75–1.77)
	NFW	8	11	37.4	23.6	1.67 (0.89–3.12)	0.90 (0.44–1.82)	5	5	18.5	20.4	1.36 (0.54–3.42)	1.97 (0.70–5.60)
					0.3246	0.4168					0.5180	0.4450	
AIDS	France	19	19	4.9	5.3	1	1	8	8	2.1	3.5	1	1
malignancies	SSA	14	14	5.9	9.5	1.21 (0.61–2.42)	1.78 (0.79–4.01)	11	11	3.3	8.0	1.57 (0.63–3.90)	2.31 (0.81–6.61)
	NFW	1	1	3.4	3.0	0.69 (0.09–5.18)	0.56 (0.06–4.98)	0	0	-	-	-	-
						0.7724	0.2896					0.3051	0.1291
Non-AIDS	France	71	77	19.9	29.1	1	1	55	59	15.7	31.6	1	1
bacterial infections	SSA	53	62	26.3	45.4	1.33 (0.95–1.85)	1.56 (1.07–2.29)	36	41	12.4	34.5	0.79 (0.53–1.18)	1.09 (0.70–1.71)
	NFW	10	10	34.0	49.5	1.71 (0.89–3.31)	1.70 (0.82–3.56)	6	6	22.2	50.6	1.41 (0.61–3.28)	1.60 (0.58–4.39)
						0.1253	0.0477					0.3102	0.6502
Other non-AIDS	France	38	39	10.0	16.4	1	1	29	29	7.7	4.7	1	1
infections	SSA	31	31	13.2	26.0	1.31 (0.82–2.10)	1.59 (0.93–2.72)	32	35	10.6	9.0	1.37 (0.84–2.25)	2.04 (1.18–3.53)
	NFW	3	3	10.2	12.6	1.01 (0.31–3.28)	0.77 (0.21–2.83)	6	6	22.2	36.0	2.88 (1.19–6.93)	7.87 (2.54–24.4)
						0.5332	0.1957					0.0790	0.0010
Cardiovascular	France	36	42	10.8	7.3	1	1	25	27	7.2	11.9	1	1
diseases	SSA	19	20	8.5	7.9	0.78 (0.46–1.33)	1.08 (0.59–1.95)	10	10	3.0	5.8	0.42 (0.20–0.87)	0.49 (0.21–1.13)
	NFW	3	3	10.2	11.4	0.94 (0.29–3.04)	1.56 (0.44–5.55)	0	0	-	-	-	-
						0.6608	0.8016					0.0121	0.0240
Central	France	27	30	1.8	1.4	1	1	24	25	4.3	7.8	1	1
neurological and psychiatric disorders	SSA	8	8	0.4	0.6	0.24 (0.03–1.91)	0.40 (0.04–3.60)	17	19	1.8	3.6	0.43 (0.17–1.09)	0.45 (0.16–1.31)
	NFW	2	2	3.4	4.6	1.88 (0.23–15.30)	3.30 (0.23–47.90)	4	4	7.4	8.8	1.74 (0.40–7.56)	1.12 (0.20–6.31)
						0.1997	0.4395					0.1006	0.3042
Non-AIDS	France	33	36	9.3	10.9	1	1	21	24	6.4	8.7	1	1
malignancies	SSA	9	12	5.1	8.8	0.55 (0.29–1.05)	0.80 (0.38–1.67)	9	9	2.7	5.9	0.43 (0.20–0.92)	0.68 (0.29–1.58)
	NFW	1	2	6.8	7.6	0.73 (0.18–3.04)	0.70 (0.15–3.11)	0	0	-	-	-	-
						0.1669	0.7589					0.0208	0.1932
Iatrogenic	France	20	21	5.4	9.6	1	1	24	26	6.9	7.4	1	1
effects	SSA	9	9	3.8	7.7	0.71 (0.32–1.54)	0.80 (0.32–2.00)	17	17	5.2	6.3	0.74 (0.40–1.37)	0.85 (0.43–1.71)
	NFW	1	1	3.4	3.7	0.63 (0.08–4.66)	0.38 (0.05–3.28)	1	1	3.7	5.8	0.53 (0.07–3.94)	0.78 (0.09–6.83)
						0.6274	0.5875					0.5504	0.8923

Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral therapy

^aAdjusted for variables at cART initiation: age, the region of care, the CD4 cell count, the pVL, pre-existing AIDS status, hepatitis B virus antigen and/or anti-hepatitis C virus antibody status, and the smoking status for all analyses, plus the body mass index for cardiovascular diseases

<https://doi.org/10.1371/journal.pone.0205385.t002>

and NFW migrants (respectively 1.40 (95%CI: 0.99–1.97) and 2.91 (95%CI: 1.36–6.22)) than among French natives, due to a higher aRR of non-AIDS non-bacterial infections (Table 2). The main non-AIDS bacterial infection was acute pneumonia, with 29 cases (27.4%), and the main non-AIDS non-bacterial infections were non-bacterial diarrhea (11 cases, 15.7%), viral meningo-encephalitis (10 cases, 14.3%), herpes zoster (9 cases, 12.8%) and malaria (6 cases, 8.6%). No other significant differences were observed in the aRR of cardiovascular diseases, neurological/psychiatric disorders, non-AIDS malignancies, or iatrogenic disorders according to geographic origin, although SSA migrants had lower crude RRs for cardiovascular and for non-AIDS malignancies events/deaths than French native women.

Discussion

We found that the likelihood of non-AIDS infections, and particularly bacterial infections, was significantly higher among male migrant from sub-Saharan Africa than among male French natives. The likelihood of non-AIDS infections, particularly non-bacterial infections, was significantly higher among female migrants from sub-Saharan Africa and non-French West Indies than among female French natives.

A recent collaborative cohort study comparing mortality in Western Europe according to geographic origin, sex and HIV transmission category [17] showed that, compared to native heterosexual men, mortality was lower among male heterosexual SSA migrants and similar among male heterosexual Caribbean migrants, whereas, compared to female heterosexual natives, mortality among female heterosexual SSA migrants was similar and mortality among female heterosexual Caribbean migrants was higher. Differences among host countries were not analyzed, despite differences in recruitment to this study, as well as differences in social determinants [18], including access to HIV screening, health care and antiretroviral therapy [19,20]. In addition, for a given country of origin, social determinants and access to medical services might have been influenced by the migrants' native language(s) [20,21]. Non-AIDS morbidity has not previously been studied according to geographic origin.

Non-AIDS-defining events, and especially bacterial infections, now represent the leading cause of severe morbidity among HIV-infected patients [22,23,24]. Immunosuppression, even when moderate, is associated with an increased risk of bacterial, viral, fungal and parasitic infections [7,25,26]. We found that the risk of infection among heterosexual migrants from SSA or NFW was higher than among their native French counterparts. We could not explore the reasons for this difference, but one explanation might be exposure to infectious pathogens during visits to the country of origin as migrants travel more to the tropics than non migrants in Western Europe [27]. This implies a need for tailored counseling to ensure that migrants travel with enough and adequate medications, including antiretroviral drugs and antimalarial prophylaxis [28,29,30] and that they also have adequate pneumococcal and influenza vaccination, as recommended [31]. Moreover, in addition to lower CD4 cell counts at cART initiation [32], SSA and NFW migrants tends to have lower CD4 cell recovery during the first two years of treatment [9] and might thus be more vulnerable to non-AIDS infections during this period [33].

This study has several limitations. First, no data on treatment adherence are available in the FHDH database. However, we recently showed that in women and in non homosexual men followed in France, SSA and NFW migrants had no difference in time to viral undetectability than their native French counterparts [9]. Moreover, we used an intent-to-continue-treatment approach, meaning that cART interruption, which might have differed among the groups, was not taken into account in the models. However, it is noteworthy that the median number of visits per year and the median time between visits did not differ according to geographic origin or sex (data not shown). Because FHDH is implemented in infectious diseases and internal

medicine departments, non-AIDS non-infectious events leading to hospitalization in other departments may have been under-reported, leading to an underestimation of non-AIDS events. Similarly, because a predefined hierarchy was sometimes used to classify morbidity and mortality, misclassification was possible. However, there is no reason to suspect that under-reporting of some non-AIDS events or misclassification between the different clinical categories would have differed according to geographic origin. The main strength of this study is its large size and lengthy follow-up, which allowed us to assess meaningful clinical outcomes, including serious non-AIDS events in the different subgroups.

In summary, after cART initiation, heterosexual men and women from sub-Saharan Africa and non-French West Indies have a higher risk of non-AIDS infections than their native France counterparts. However, we found no other substantial differences in terms of severe AIDS or non-AIDS events/deaths in either gender. Special attention should thus be paid to the prevention of infectious diseases among migrants, including screening of vaccination status and completion of vaccine schedules [34], pre-travel counseling to prevent gastro-intestinal diseases and to prevent malaria with exposure prophylaxis counseling and chemoprophylaxis prescription, and post-travel close monitoring of infectious tropical diseases which could unbalance their care.

Acknowledgments

Clinical Epidemiology Group of the FHDH-ANRS CO4:

Scientific committee; S Abgrall, L Bernard, E Billaud, F Boué, L Boyer, A Cabié, F Caby, A Canestri, D Costagliola, L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, H Fischer, J Gasnault, C Gaud, S Grabar, MA Khuong, O Launay, L Marchand, M Mary-Krause, S Matheron, G Melica-Grégoire, H Melliez, JL Meynard, M Nacher, J Pavie, L Piroth, I Poizot-Martin, C Pradier, J Reynes, E Rouveix, A Simon, L Slama, P Tattevin, H Tissot-Dupont.

COREVIH coordinating center: French Ministry of Health (G Astier, J Biga, T Kurth), Technical Hospitalization Information Agency, ATIH (N Jacquemet).

Statistical analysis center: UMRS 1136 INSERM et UPMC (D Costagliola, *Principal investigator*, S Abgrall, S Grabar, M Guiguet, S Lang, L Lièvre, M Mary-Krause, H Selinger-Leneman), INSERM-Transfert (V Potard).

COREVIH: Paris area: *Corevih Ile de France Centre* (GH Pitié-Salpêtrière: O Benveniste, A Simon, G Breton, C Lupin, E Bourzam; Hôpital Saint-Antoine: PM Girard, L Fonquernie, N Valin, B Lefebvre, M Sebire; Hôpital Tenon: G Pialoux, MG Lebrette, P Thibaut, A Adda, M Hamidi, J Cadranel, A Lavolé, A Parrot), *Corevih Ile de France Est* (Hôpital Saint-Louis: E Oksenhendler, L Gerard, JM Molina, W Rozenbaum, B Denis, N De Castro, C Lascoux; GH Lariboisière-Fernand Widal: JF Bergmann, V Delcey, A Lopes, P Sellier, M Parrinello; Hôpital Avicenne: O Bouchaud, N Vignier, F Méchaï, S Makhloufi, P Honoré; Hôpital Jean Verdier), *Corevih Ile de France Nord* (Hôpital Bichat-Claude Bernard: Y Yazdanpanah, S Matheron, S Lariven, V Joly, C Rioux; Hôpital Delafontaine: MA Khuong-Josses, M Poupard, B Taverne), *Corevih Ile de France Ouest* (Hôpital Ambroise Paré: E Roveix, S Greffe, C Dupont, A Freire Maresca, E Reimann; Hôpital Louis Mourier: M Bloch, F Meier, E Mortier, F Zeng, B Montoya; Hôpital Raymond Poincaré: C Perronne, P de Truchis, D Mathez, D Marigot-Outtandy, H Berthé; CH André Mignot—Le Chesnay: A Greder Belan, A Therby, C Godin Collet, S Marquet Juillet, M Ruquet, S Roussin-Bretagne, P Colardelle; Hôpital Foch—Suresnes: JE Kahn, D Zucman, C Majerholc, E Fourn, D Bornarel; Hôpital Victor Dupouy—Argenteuil: L Sutton, V Masse, P Genet, B Wifaq, J Gerbe; Hôpital Max Fourestier—Nanterre: V Daneluzzi, J Gerbe; CHI de Meulan les Mureaux: T Akpan, M Marcou; CH F Quesnay—Mantes La Jolie: F Granier, JJ Laurichesse, V Perronne; CHI de Poissy: C Veyssier-Belot, H Masson; CHI de St-

Germain-en-Laye: Y Welker, P Brazille), *Corevih Ile de France Sud* (Hôpital Européen Georges Pompidou: L Weiss, J Pavie, Ml Lucas, C Jung, M Ptak; GH Tarnier-Cochin: D Salmon, C Le Jeunne, O Launay, P Guet, MP Pietri, E Pannier Metzger, V Marcou, P Loulergue, N Dupin, JP Morini, J Deleuze, P Gerhardt, J Chanal; Hôtel Dieu: JP Viard, J Ghosn, P Gazalet, A Cros, A Maignan; Hôpital Antoine Bécère: F Boué, S Abgrall, V Chambrin, I Kansau, M Raho-Moussa; Hôpital de Bicêtre: D Vittecoq, O Derradji, C Bolliot, C Goujard, E Teicher, J Gasnault, M Mole, K Bourdic; Hôpital Henri Mondor: JD Lelievre, G Melica, M Saidani, C Chesnel, C Dumont; Hôpital Necker: C Duvivier, O Lortholary, C Rouzard, F Touam, K Benhadj; CMIP Pasteur: PH Consigny, P Bossi, A Gergely, G Cessot, F Durand).

Outside Paris area: *Corevih Alsace* (CHU de Strasbourg: D Rey, M Partisani, C Cheneau, ML Batard, P Fischer; CH de Mulhouse: G Beck-Wirth, C Michel, M Benomar), *Corevih de l'Arc Alpin* (CHU de Grenoble: P Leclercq, M Blanc, P Morand, O Epaulard, A Signori-Schmuck), *Corevih Auvergne-Loire* (CHU de Clermont-Ferrand: H Laurichesse, C Jacomet, M Vidal, D Coban, S Casanova; CHU de Saint-Etienne: A Fresard, C Guglielminotti, E Botelho-Nevers, A Brunon-Gagneux, V Ronat), *Corevih Basse-Normandie* (CHU de Caen: R Verdon, S Dargère, E Haustraete, P Féret, P Goubin), *Corevih Bourgogne* (CHU de Dijon: P Chavanet, A Fillion, L Piroth, D Croisier, S Gohier), *Corevih Bretagne* (CHU de Rennes: C Arvieux, F Souala, JM Chapplain, M Ratajczak, J Rohan), *Corevih Centre et Poitou Charentes* (CHRU de Tours), *Corevih Franche-Comté* (CHRU de Besançon: C Chirouze, L Hustache-Mathieu, JF Faucher, A Proust, N Magy-Bertrand, H Gil, N Méaux-Ruault; CH de Belfort: JP Faller, O Ruyer, V Gendrin, L Toko); *Corevih Haute-Normandie* (CHU de Rouen), *Corevih Languedoc-Roussillon* (CHU de Montpellier; CHU de Nîmes: A Sotto, I Rouanet, JM Mauboussin, R Doncesco, G Jacques), *Corevih Lorraine Campagne-Ardenne* (Nancy Hôpital de Brabois: T May, C Rabaud, M Andre, M Delestan, MP Bouillon; CHU de Reims: F Bani-Sadr, C Rouger, JL Berger, Y Nguyen), *Corevih de Midi-Pyrénées Limousin* (Toulouse CHU Purpan: B Marchou, P Delobel, G Martin Blondel, L Cuzin, N Biezunski, L Alric, D Bonnet, M Guivarch, A Palacin, V Payssan), *Corevih Nord-Pas de Calais* (CH de Tourcoing: H Melliez, F Ajana, A Meybeck, N Viget), *Corevih PACA Est* (Nice Hôpital Archet 1: C Pradier, P Pugliese, PM Roger, E Rosenthal, J Durant, E Cua, A Naqvi, I Perbost, K Rizzo; CH Antibes-Juan les Pins: D Quinsat; CHI de Fréjus/St Raphaël: P Del Giudice; CH de Grasse: PY Dides), *Corevih PACA Ouest* (Marseille Hôpital de la Conception: P Enel, R Sambuc, MS Antolini-Bouvenot, P Druart, L Meddeb, I Ravaux, A Menard, C Tomei, C Dhiver, H Tissot-Dupont; Marseille Hôpital Nord: J Moreau, S Mokhtari, MJ Soavi, V Thomas; Marseille Hôpital Sainte-Marguerite: I Poizot-Martin, S Bregigeon, O Faucher, V Obry-Roguet, AS Ritleng, N Petit; Marseille Centre pénitentiaire des Baumettes: C Bartoli, JM Ruiz, D Blanc; CH d'Aix-En-Provence: T Allegre, M Sordage, JM Riou, C Faudon; CH d'Avignon: B Slama, H Zerazhi, O Boulat, S Chebrek, M Beyrne; CH de Digne Les Bains: P Granet Brunello; CH de Gap: L Pellissier, D Bonnabel; CH de Martigues: R Cohen Valensi, B Mouchet, G Mboungou; CHI de Toulon: A Lafeuillade, E Hope-Rapp, G Hittinger, G Philip, V Lambry), *Corevih Pays de la Loire* (CHU de Nantes: F Raffi, C Allavena, E Billaud, N Hall, V Reliquet), *Corevih de la Vallée du Rhône* (Lyon Hôpital de la Croix-Rousse: C Chidiac, L Cotte, T Ferry, T Perpoint, P Miaillhes; Lyon Hôpital Edouard Herriot: A Boibieux, JM Livrozet, D Makhloufi, F Brunel, P Chiarello).

Overseas: *Corevih Guadeloupe* (CHU de Pointe-à-Pitre: B Hoen, I Lamaury, I Fabre, K Samar, E Duvalon; CH Saint-Martin: C Clavel, S Stegmann, V Walter), *Corevih Guyane* (CH de Cayenne: M Nacher, L Adriouch, F Huber, V Vanticlke, P Couppié), *Corevih Martinique* (CHU de Fort-de-France: A Cabié, S Abel, S Pierre-François), *Corevih de La Réunion* (CHU Félix Guyon: C Gaud, C Ricaud, R Rodet, G Wartel, C Sautron; GH Sud Réunion: P Poubeau, G Borgherini, G Camuset).

Author Contributions

Conceptualization: Laure-Amélie de Monteynard, Dominique Costagliola, Sophie Abgrall.

Data curation: Laure-Amélie de Monteynard.

Formal analysis: Laure-Amélie de Monteynard.

Funding acquisition: Dominique Costagliola.

Investigation: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Anne Simon, Sophie Abgrall.

Methodology: Laure-Amélie de Monteynard, Sophie Grabar, Rosemarie Dray-Spira, Dominique Costagliola, Sophie Abgrall.

Project administration: Dominique Costagliola.

Supervision: Dominique Costagliola, Sophie Abgrall.

Validation: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Dominique Costagliola, Sophie Abgrall.

Visualization: Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Sophie Abgrall.

Writing – original draft: Laure-Amélie de Monteynard, Sophie Abgrall.

Writing – review & editing: Laure-Amélie de Monteynard, Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Dominique Costagliola, Sophie Abgrall.

References

1. Costagliola D, May M. Survival in individuals living with HIV. *Curr Opin HIV AIDS* 2016; 11:451–4. <https://doi.org/10.1097/COH.0000000000000304> PMID: 27716729
2. Gill J, May M, Lewden M, Saag M, Mugavero M, Reiss P, et al. for the Antiretroviral Therapy Cohort Collaboration Study Group. Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies. *Clin Infect Dis* 2010; 50:1387–96. <https://doi.org/10.1086/652283>
3. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al.: EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. *J Acquir Immune Defic Syndr* 2010; 55:262–270. <https://doi.org/10.1097/QAI.0b013e3181e9be6b> PMID: 20700060
4. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001–2008. *J Acquir Immune Defic Syndr* 2012; 59:368–375. <https://doi.org/10.1097/QAI.0b013e318246b862> PMID: 22240460
5. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al.: ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS* 2014; 28:1181–91. <https://doi.org/10.1097/QAD.0000000000000222> PMID: 24901259
6. Grinsztejn B, Hosseinipour MC, Ribaud HJ, Swindells S, Eron J, Chen YQ, et al.: HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis* 2014; 14:281–90. [https://doi.org/10.1016/S1473-3099\(13\)70692-3](https://doi.org/10.1016/S1473-3099(13)70692-3) PMID: 24602844
7. Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, et al.; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS CO3 Study Group. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral

- therapy, France and Brazil, 2000–2008: hospital-based cohort studies. *BMC Infect Dis* 2014; 14:278. <https://doi.org/10.1186/1471-2334-14-278> PMID: 24885790
8. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med* 2015; 373:795–807. <https://doi.org/10.1056/NEJMoa1506816> PMID: 26192873
 9. de Monteynard LA, Matheron S, Gilquin J, Pavie J, de Truchis P, Grabar S, et al.; FHDH-ANRS CO4. Influence of geographic origin, sex and HIV transmission group on the outcome of first-line combined antiretroviral therapy (cART) in France. *AIDS* 2016; 30:2235–46. <https://doi.org/10.1097/QAD.0000000000001193> PMID: 27428741
 10. Shepherd BS, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, et al., for the Antiretroviral Therapy Cohort Collaboration (ART-CC). Higher rates of AIDS during the first year of therapy among migrants: the importance of tuberculosis. *AIDS* 2013; 27:1321–9. <https://doi.org/10.1097/QAD.0b013e32835faa95> PMID: 23925379
 11. Monge S, Alejos B, Dronda F, Del Romero J, Iribarren JA, Pulido F, et al.; CoRIS. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain. *HIV med* 2013; 14:273–83. <https://doi.org/10.1111/hiv.12001> PMID: 23171059
 12. Del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczar D, et al. for the Antiretroviral Therapy Collaboration (ART-CC). Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States. *Clin Infect Dis* 2013; 56:1800–9. <https://doi.org/10.1093/cid/cit111>
 13. Mary-Krause M, Grabar S, Lievre L, Abgrall S, Billaud E, Boue F, et al. Cohort Profile: French Hospital Database on HIV (FHDH-ANRS CO4). *Int J Epidemiol* 2014; 43:1425–36. <https://doi.org/10.1093/ije/dyu002> PMID: 24550249
 14. Thierry X. International migrations in Europe: towards harmonization of statistics. *INED Populat Soc* 2008; 442:1–4. Available at: <http://www.ined.fr/en/publications/population-and-societies/harmonization-european-statistics-international-migration/> Accessed 30 January 2017.
 15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 1992; 41:RR-17: 1–19. PMID: 1361652
 16. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. *N Engl J Med* 2015; 373:808–22. <https://doi.org/10.1056/NEJMoa1507198> PMID: 26193126
 17. Monge S, Jarrin I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, et al.; Migrants Working Group on behalf of COHERE in EuroCoord. Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study. *Lancet HIV* 2015; 2:e540–9. [https://doi.org/10.1016/S2352-3018\(15\)00203-9](https://doi.org/10.1016/S2352-3018(15)00203-9)
 18. Del Amo J, Lodi S, Dray-Spira R, Wittkop L, Monge S, Braun D, et al. The Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Coord. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. *AIDS* 2017; 31:253–62. <https://doi.org/10.1097/QAD.0000000000001270>
 19. European Centre for Disease Control and Prevention (ECDC). Thematic report: migrants monitoring implementation of the dublin declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2012 progress. 2013 Available at: <http://ecdc.europa.eu/en/publications/Publications/dublin-declaration-monitoring-report-migrants-september-2013.pdf> Accessed 24 January 2017.
 20. O'Donnell C, Burns N, Dowrick C, Lionis C, MacFarlane A; RESTORE team. Health-care access for migrants in Europe. *Lancet* 2013; 382:393.
 21. Abgrall S, Del Amo J. Effect of sociodemographic factors on survival of people living with HIV. *Curr Opin HIV AIDS* 2016; 11:501–06. <https://doi.org/10.1097/COH.0000000000000301> PMID: 27272536
 22. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, et al., ANRS CO8 (APROCO-COPILOTE) Study Group. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO-COPILOTE (ANRS CO8) cohort study. *J Acquir Immune Defic Syndr* 2009; 51:407–415. <https://doi.org/10.1097/QAI.0b013e3181acb65f> PMID: 19474755
 23. Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, et al.; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. *PLoS One* 2014; 9:e102671. <https://doi.org/10.1371/journal.pone.0102671> PMID: 25076050
 24. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. *Lancet HIV* 2015; 2:e438–444. [https://doi.org/10.1016/S2352-3018\(15\)00137-X](https://doi.org/10.1016/S2352-3018(15)00137-X) PMID: 26423651

25. Collin A, Le Marec F, Vandenhende MA, Lazaro E, Duffau P, Cazanave C, et al., ANRS CO3 Aquitaine Cohort Study Group. Incidence and risk factors for severe bacterial infections in people living with HIV. ANRS CO3 Aquitaine Cohort, 2000–2012. *PloS One* 2016; 11:e0152970. <https://doi.org/10.1371/journal.pone.0152970> PMID: 27050752
26. van Veen KEB, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in patients with HIV: A population-based prospective study. *J Infect* 2016; 72:362–368. <https://doi.org/10.1016/j.jinf.2016.01.001> PMID: 26774622
27. Gebreselassie HM, Kraus D, Fux CA, Haubitz S, Scherrer A, Hatz C, et al. Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study. *HIV Medicine* 2017; 18:564–72. <https://doi.org/10.1111/hiv.12491> PMID: 28247589
28. Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, et al. Imported Malaria in HIV-Infected Patients Enrolled in the ANRS CO4 FHDH Study. *J Acquir Immune Defic Syndr* 2008; 49:55–60. <https://doi.org/10.1097/QAI.0b013e31817e635b> PMID: 18667929
29. Abgrall S, Fugon L, Lélé N, Carde E, Bentata M, Patey O, et al. and the ANRS VIHVO Study Group. Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country. *Int J STD AIDS* 2014; 25:389–90. <https://doi.org/10.1177/0956462413506894> PMID: 24667876
30. Ansart S, Caumes E. Pneumopathies au retour de voyage. *Rev Mal Respir* 2002; 18:693–697. Available at: <http://www.em-consulte.com/rmr/article/151537>. Accessed 30 January 2017.
31. Yéni P et le groupe d'experts sur l'infection à VIH. Prise en charge médicale des personnes infectées par le VIH. Paris: Flammarion médecine-sciences 2008. Available at: <http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/084000593.pdf> Accessed 31 January 2016.
32. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, et al.; French Hospital Database ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003–2009). *J Acquir Immune Defic Syndr* 2013; 64:197–203. <https://doi.org/10.1097/QAI.0b013e31829cfbfa> PMID: 24047970
33. Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, et al., Italian MASTER Cohort. Risk of Severe NON AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts > 200/μl Despite Effective HAART. *PloS One* 2015; 10(5):e0124741. <https://doi.org/10.1371/journal.pone.0124741> PMID: 26020949
34. Mullaert J, Abgrall S, Lele N, Batteux F, ben Slama L, Meritet JF, et al.; for the ANRS VIHVO Study Group. Diphtheria, Tetanus, Poliomyelitis, Yellow Fever and Hepatitis B Seroprevalence among HIV1-infected Migrants. Results from the ANRS VIHVO vaccine sub-study. *Vaccine* 2015; 33:4938–44. <https://doi.org/10.1016/j.vaccine.2015.07.036> PMID: 26209841